Champions Oncology (CSBR) Income from Non-Controlling Interests (2025)
Champions Oncology (CSBR) recorded quarterly Income from Non-Controlling Interests of -$31000.0 in Q4 2025, down 3.33% quarter-over-quarter from -$30000.0 in Q3 2025.
Champions Oncology (CSBR) Income from Non-Controlling Interests (2025) Analysis & Trends
Champions Oncology's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at -$31000.0 for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -31,000.00 |
| Jul 31, 2025 | -30,000.00 |